Stocks · News reference
JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
Filed: 2026-09-18 AccNo: 0001193125-26-395031 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits